World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
37821
World Ranking
9971
National Ranking
5132

Richard L. Theriault publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard L. Theriault sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 303 publications — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard L. Theriault D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard L. Theriault sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard L. Theriault is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research intersects oncology with economic and financial perspectives, focusing on the impacts and risk factors associated with cancer.

The scientist's recent publications cover topics related to cancer research and economics. Notable papers include:

  • EP.04A.08 Leveraging the Quebec Lung Cancer Screening Program to Create a Collaborative Biobanking Project for Research Purposes, 2024, Journal of Thoracic Oncology
  • Abstract P4-14-02: Cohort study of women treated with chemotherapy for breast cancer during pregnancy compared with non-pregnant breast cancer patients, 2020, Cancer Research

Frequently collaborating with other researchers, Richard L. Theriault has worked alongside:

  • Sophie Plante
  • Sabrina Biardel
  • Andrea Mogas
  • Margaret Allard
  • Samuel Martel

Their contributions appear in specialist journals such as:

  • Journal of Thoracic Oncology
  • Cancer Research

Their research fields include oncology and economics and econometrics, reflecting a multidisciplinary approach.

Main topics of investigation in their work are:

  • Economic and Financial Impacts of Cancer
  • Cancer Risks and Factors

Best Publications

  • Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    S. Eva Singletary;Craig Allred;Pandora Ashley;Lawrence W. Bassett

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

    Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar

  • Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

    Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney

  • Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

    Allan Lipton;Richard L. Theriault;Gabriel N. Hortobagyi;Joseph Simeone

  • Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel

    Nuhad K. Ibrahim;Neil Desai;Sewa Legha;Patrick Soon-Shiong

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

    Gabriel N. Hortobagyi;Richard L. Theriault;Allan Lipton;Lester Porter

  • The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial

    Jeffrey S. Wefel;Renato Lenzi;L D O Richard Theriault;Robert N. Davis

  • Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

    Richard L. Theriault;Allan Lipton;Gabriel N. Hortobagyi;Richard Leff

  • Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

    Nancy U. Lin;Ann Vanderplas;Melissa E. Hughes;Richard L. Theriault

  • Breast cancer: Clinical practice guidelines in oncology

    Robert W. Carlson;Benjamin O. Anderson;Harold J. Burstein;Charles E. Cox

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Management of Breast Cancer During Pregnancy Using a Standardized Protocol

    David L. Berry;Richard L. Theriault;Frankie A. Holmes;Valerie M. Parisi

  • High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

    Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

  • Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation

    Angela Katz;Eric A. Strom;Thomas A. Buchholz;Howard D. Thames

  • Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero

    Karin M.E. Hahn;Peter H. Johnson;Nancy Gordon;Henry Kuerer

  • Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

    Vicente Valero;Frankie A. Holmes;Ronald S. Walters;Richard L. Theriault

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Stephen B. Edge
Stephen B. Edge Roswell Park Cancer Institute
Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Jane C. Weeks
Jane C. Weeks Harvard University
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Eric P. Winer
Eric P. Winer Yale University
S. Eva Singletary
S. Eva Singletary The University of Texas MD Anderson Cancer Center
Clifford A. Hudis
Clifford A. Hudis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring healthcare careers beyond a traditional medical degree, there are several flexible online options to consider. For those interested in advanced practice roles without a nursing background, msn direct entry programs online offer a fast track to becoming a nurse leader, even for non-nursing graduates.

Entry-level nursing pathways are also widely accessible. Many students opt for accredited online adn programs, which provide foundational nursing education with greater flexibility—ideal for those balancing work or family commitments.

Not every healthcare career requires direct patient care. Administrative roles like medical billing and coding are in high demand and can be started quickly. If affordability is a key concern, consider choosing from online medical billing and coding schools that accept fafsa.

Admission processes vary: some nursing schools require prerequisite exams, while others do not. If you’re concerned about entrance tests, you may want to look for programs that answer the question, do you have to take the teas test to get into nursing school.

Best Scientists Citing Richard L. Theriault

Trending Scientists